Innovation in Standard of Care: PARP Inhibitors Approved for All Patients

On the 27th of March 2017, Tesaro’s PARP inhibitor named Zejula received FDA regulatory approval for the treatment of all recurrent epithelial ovarian cancer patients - irrespective of their BRCA 1/2 status. This is a major contribution to the current treatment regimen for these patients, who previously had less than a 30% chance of qualifying for treatment with this life-prolonging drug.


This paradigm shift in care was initiated by the results generated from the 553-patient NOVA study led by OvaCure’s collaborating principal investigator, Dr. Mansoor Raza Mirza. The trial revealed that all patients experienced significant clinical benefit from treatment with PARP inhibitors. Progression-free survival for patients treated with Zejula was up to 21 months. While those treated with a placebo, experienced a maximum of 5.5 months without progression of the disease.

This approval provides future relapsed patients with hope of better management of their disease, improved quality of life and a step closer to the cure. European approval of the use of Zejula for all epithelial ovarian cancer patients is currently under review.

OvaCure is proud to collaborate with Principal Investigator of this trial, Dr. Mansoor Raza Mirza in our Tumour-Match Project.